John L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers

Articles

Perspectives on Treating CCA Moving Forward

May 3rd 2021

A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.

Immunotherapy for Advanced Cholangiocarcinoma

May 3rd 2021

The role of MSI testing and potential use of immunotherapy to treat patients with advanced cholangiocarcinoma.

Cholangiocarcinoma: Potential Therapies Under Investigation

April 26th 2021

An overview of various treatment opportunities under study that are looking at using novel techniques to help personalize treatment for patients with bile duct cancers.

IDH Targeting in Advanced Cholangiocarcinoma

April 26th 2021

Considerations for treating appropriate patients with advanced cholangiocarcinoma with an IDH inhibitor.

Implications for Using FGFR Inhibitors in Advanced CCA

April 19th 2021

Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, explains what GI oncologists can expect from FGFR treatment for advanced cholangiocarcinoma in terms of treatment responses.

FGFR Inhibitors for Advanced Cholangiocarcinoma: Adverse Events

April 19th 2021

Recommendations for appropriately managing patients who experience adverse events associated with FGFR treatment for advanced cholangiocarcinoma.

FGFR Inhibitors for Advanced Cholangiocarcinoma

April 12th 2021

R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, comments on the rationale for treating patients with advanced cholangiocarcinoma with an FGFR inhibitor.

Promoting the Importance of Molecular Testing in CCA

April 12th 2021

The value of early molecular testing in cholangiocarcinoma and importance of promoting its role to both patients and GI oncologists.

Open Questions and Future Directions in mCRC

February 4th 2021

Experts in CRC discuss questions and management of mCRC.

Using Molecular Testing to Guide Treatment Selection in mCRC

February 4th 2021

John Marshall, MD, and Axel Grothey, MD, discuss how molecular testing results guide treatment decisions in patients with mCRC.

TAS-102 in Third or Fourth Line for mCRC

February 1st 2021

Experts in mCRC review data on TAS-102 and discuss how best to sequence therapies in the third or fourth line.

Regorafenib in Third or Fourth Line for mCRC: Safety in the Re-DOS Trial

February 1st 2021

Axel Grothey, MD, and John Marshall, MD, discuss safety results from the ReDOS study of regorafenib in patients with mCRC.

Regorafenib in Third or Fourth Line for mCRC: Efficacy in the Re-DOS Trial

February 1st 2021

John Marshall, MD, reviews efficacy data from the ReDOS study of regorafenib in patients with mCRC.

Therapy After Progression in mCRC

February 1st 2021

Experts in metastatic colorectal cancer review therapeutic options after progression for patients with mCRC.

Maintenance or Chemo-Free Interval in mCRC

January 29th 2021

Experts in metastatic colorectal cancer discuss when and in which patients to use a chemotherapy-free treatment interval.

Optimizing First-Line Therapy in mCRC

January 29th 2021

Axel Grothey, MD, and John Marshall, MD, discuss strategies for optimizing first-line treatment in metastatic colorectal cancer and the role of adjuvant therapy.

First-Line Options in mCRC

January 22nd 2021

Axel Grothey, MD, and John Marshall, MD, discuss first-line treatment options in patients with metastatic colorectal cancer.

Treatment Considerations in mCRC

January 22nd 2021

Axel Grothey, MD, discusses factors that influence treatment selection in patients with mCRC.